Timothy Lewis Cannon

ORCID: 0000-0001-5033-3071

1

h-index

1

Publications

2,448

Citations

Publications

1 shown

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu , Richard S. Finn , Julien Edeline +56 more

2018 The Lancet Oncology 2448 citations

Frequent Co-Authors

Andrew X. Zhu

Harvard University

Richard S. Finn

UCLA Jonsson Comprehensive Cancer Center

Julien Edeline

Centre Eugène Marquis

Stéphane Cattan

Hôpital Claude Huriez

Sadahisa Ogasawara

Chiba University

Daniel H. Palmer

University of Liverpool

Researcher Info

h-index: 1
Publications: 1
Citations: 2,448

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-5033-3071

Impact Metrics

h-index 1

h-index: Number of publications with at least h citations each.